MONARCH 3: Interim overall survival (OS) results of abemaciclib plus a nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+, HER2- advanced breast cancer (ABC) - Goetz, M P; Toi, M; Huober, J (Ann Oncol, 2022)